The URAC awards KSP as a top-performing
specialty pharmacy committed to making key contributions to advance
performance measurement within accreditation programs
DETROIT, June 26,
2024 /PRNewswire/ -- The Utilization Review
Accreditation Commission (URAC) has once again awarded KSP,
McLaren's Specialty Pharmacy, as a 2023 Pioneer in URAC's Leaders
in Performance Measurement (LPM) recognition program. As a
URAC-accredited organization, this distinction shows that KSP
continues to demonstrate a commitment to improving health care
quality and well-being through performance measurement.
As a specialty pharmacy, KSP provides needed medications and
therapeutics at an affordable cost for patients with complex
diseases or whose care requires high-cost treatments. Physicians
utilize KSP to fill prescriptions to treat cancer, HIV,
gastrointestinal diseases, neurological disorders, and more at an
affordable cost to the patient. Being a Pioneer in Performance
Management means KSP is going above mandatory reporting
requirements, which helps to provide insights into cutting-edge
measurement concepts.
"We're elated to be announced as a Pioneer for the second year
in a row. KSP is committed to the patients we serve. In the work
that we do to help their health care needs, we want to ensure we
are making a difference," said Stephen
Kaurala, PharmD, MBA, BCOP, KSP pharmacy manager. "Our team
does a tremendous job at ensuring a seamless continuum of care
through each patient's therapy journey."
Within the URAC's LPM programs, this award recognizes KSP as a
leader among the Specialty Pharmacy programs. When evaluating
specialty pharmacies, the URAC's Quality, Research and Measurement
Team considered data submitted in 2023, which was collected between
January 1 through December 31, 2022.
Along with the data, specialty pharmacies must meet specific
criteria, including holding a current and full URAC accreditation
status, submitting measures on time for the reporting period, and
participating in key activities beyond mandatory requirements. This
is KSP's second time receiving LPM recognition.
"As McLaren's preferred specialty pharmacy, KSP fills the need
for many patients throughout Michigan who need unique medications not found
at their local pharmacy," said Brian Gamble, president
of the Karmanos Cancer Hospital and Karmanos Cancer Network. "KSP
staff has worked diligently to improve the health and well-being of
the patients McLaren serves. I am very proud of this dedication to
quality and service, KSP's hard work on exceeding accreditation
standards, and being named a Pioneer by URAC."
KSP achieved URAC Specialty Pharmacy reaccreditation in
August 2023, after first receiving
the achievement in 2020. For full accreditation, the organization
is evaluated based on risk management standards, operations and
infrastructure, performance monitoring and improvement, consumer
protection and empowerment, pharmacy operations, medication
distribution, patient service and communication, patient
management, and reporting performance measures to the URAC.
As an extension of the Barbara Ann Karmanos Cancer Institute,
part of McLaren Health Care, KSP has grown to assist with the
specialty needs of all McLaren patients in Michigan, Ohio and Indiana. Learn more about KSP at
ksppharmacy.org.
About McLaren Health Care
McLaren Health
Care, headquartered in Grand Blanc,
Michigan, is a $6.6 billion,
fully integrated health care delivery system committed to quality,
evidence-based patient care and cost efficiency. The McLaren system
includes 14 hospitals in Michigan,
ambulatory surgery centers, imaging centers, a 490-member employed
primary and specialty care physician network, commercial and
Medicaid HMOs covering more than 732,838 lives in Michigan and Indiana, home health, infusion and hospice
providers, pharmacy services, a clinical laboratory network and a
wholly owned medical malpractice insurance company. McLaren
operates Michigan's largest
network of cancer centers and providers, anchored by the Karmanos
Cancer Institute, one of only 53 National Cancer
Institute-designated comprehensive cancer centers in the U.S.
McLaren has 28,000 full-, part-time and contracted employees and
more than 113,000 network providers throughout Michigan, Indiana and Ohio. Learn more at
mclaren.org.
About the Barbara Ann Karmanos Cancer
Institute
Karmanos Cancer Institute is a leader in
transformative cancer care, research and education through courage,
commitment and compassion. The Karmanos vision is a world free of
cancer. As part of McLaren Health Care, Karmanos is the largest
provider of cancer care and research in Michigan. For more than 75 years, the
administrative and research headquarters, along with the premier
specialty cancer hospital, have been located in downtown
Detroit. With 16 network sites,
Karmanos delivers world-renowned care and access to clinical trials
throughout Michigan and northern
Ohio. The National Cancer
Institute recognizes Karmanos as one of the best cancer centers in
the nation with a comprehensive cancer center designation. Its
academic partnership with the Wayne State
University School of Medicine provides the framework for
cancer research and education – defining new standards of care and
improving survivorship. For more information, call 1-800-KARMANOS
(800-527-6266) or visit www.karmanos.org. Follow Karmanos
on Facebook, Twitter, LinkedIn and YouTube.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ksp-mclarens-specialty-pharmacy-recognized-as-a-leader-in-performance-measurement-for-second-consecutive-year-302183372.html
SOURCE Karmanos Cancer Institute